Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 14Active not recruiting 7Not yet recruiting 6Terminated 4Completed 4Withdrawn 2Approved for marketing 1

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 360Neoplasms 255Carcinoma, Non-Small-Cell Lung 199Colorectal Neoplasms 183Lung Neoplasms 152Prostatic Neoplasms 151Carcinoma, Hepatocellular 128Leukemia, Myeloid, Acute 96Pancreatic Neoplasms 86Multiple Myeloma 84Neoplasm Metastasis 74Recurrence 71Uterine Cervical Neoplasms 69Rectal Neoplasms 68Stomach Neoplasms 65Ovarian Neoplasms 65Triple Negative Breast Neoplasms 60Squamous Cell Carcinoma of Head and Neck 57Head and Neck Neoplasms 54Glioblastoma 54Brain Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47Melanoma 44Esophageal Neoplasms 43Disease 43Colonic Neoplasms 42Hematologic Neoplasms 41Glioma 40

Interventions

pyrotinib 3pertuzumab 2Trastuzumab 2neratinib 1exemestane 1dalpiciclib 1Leuprolide 1Goserelin 1Fulvestrant 1Docetaxel 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Breast Cancer × 1 year × Clear all
NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting
42 enrolled
Breast

HER2-positive Breast Cancer

NCT07198672 2025-09-30

Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

Henan Cancer Hospital

Phase NA Not yet recruiting
45 enrolled
Breast

HER2-positive Breast Cancer

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
80 enrolled
Breast

HER2-positive Breast Cancer

NCT06973525 2025-08-05

HER2-DM-NACT

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
30 enrolled
Breast

HER2-positive Breast Cancer

NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡